Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

How much do we have to pay for how many interim analyses?

Armin Koch1

  • 1Biostatistics and Experimental Design, Federal Institute for Drugs and Medical Devices, Kurt-Georg-Kiesinger-Allee 3 D-53175 Bonn, Germany. a.koch@bfarm.de

Contemporary Clinical Trials
|April 20, 2005
PubMed
Summary

This study highlights the flexibility in interim analysis timing and alpha spending in clinical trials. However, preserving alpha for the final analysis often leads to overlooking practical issues with small alpha allocations in early interim analyses.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparison of three different hpv self-sampling tools - a subanalysis of the prospective, randomized hannover self-collection study.

Archives of gynecology and obstetrics·2026
Same author

DIGIT-HF: Results From the Win Ratio Analyses.

Circulation. Heart failure·2026
Same author

Digitoxin in heart failure with reduced ejection fraction according to atrial fibrillation status: the DIGIT-HF trial.

European heart journal·2026
Same author

A Statistical Concept for Conditional Marketing Authorisation Based on the Intermediate and Final Outcomes of a Single Confirmatory Randomised Clinical Trial.

Pharmaceutical statistics·2026
Same author

Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction.

The New England journal of medicine·2025
Same author

Randomization in phase II trials: No exemption based on sample size.

British journal of clinical pharmacology·2025

Area of Science:

  • Biostatistics
  • Clinical Trial Methodology

Background:

  • Clinical trials offer flexibility in interim analysis timing and type I error (alpha) allocation.
  • Current practices often prioritize preserving alpha for the final analysis.

Purpose of the Study:

  • To examine the methodological flexibility in interim analyses and alpha spending.
  • To address the common practice of preserving alpha for final analyses and its implications.

Main Methods:

  • Methodological review of statistical approaches for interim analyses.
  • Analysis of alpha spending strategies in sequential trial designs.

Main Results:

  • Significant flexibility exists in planning interim analyses and allocating type I error.

Related Experiment Videos

  • A tendency exists to conserve alpha for the final analysis, potentially neglecting interim consequences.

    • Conclusions:

    • While flexible, alpha spending strategies in interim analyses require careful consideration of practical consequences.
    • Methodological advancements should be accompanied by a thorough understanding of their real-world impact on trial integrity.